Anti-FAP CAR T cell therapy - Tmunity Therapeutics/University of Pennsylvania
Alternative Names: TmFAP 01 CAR-TLatest Information Update: 28 Apr 2024
At a glance
- Originator Tmunity Therapeutics; University of Pennsylvania
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 22 Feb 2023 Tmunity Therapeutics has been acquired by Kite Pharma
- 18 Jan 2021 Anti-FAP CAR T cell therapy - Tmunity Therapeutics/University of Pennsylvania is available for licensing as of 18 Jan 2021. https://www.tmunity.com/